New Diagnostic Approaches in the Management of Inflammatory Lung Diseases
Starting soon · Not applicable
Conditions studied: Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis
In brief
Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are major causes of morbidity and mortality worldwide. Their development and progression are influenced by environmental exposures, such as cigarette smoking and air pollution, as well as genetic susceptibility. Despite advances in disease management, early diagnosis, accurate differential diagnosis, personalized treatment, and continuous monitoring remain significant clinical challenges. This project aims to improve the management of inflammatory lung diseases through the development and validation of innovative diagnostic, monitoring, and therapeutic approaches. The study will identify and validate multi-omics biomarkers for the differential diagnosis and prognosis of COPD, IPF, and related respiratory diseases, using machine learning techniques to develop diagnostic and prognostic biochips. Environmental determinants, including indoor and outdoor exposome factors, will be assessed to better understand their contribution to pulmonary inflammation and disease progression. The project will also develop nanotechnology-based therapeutic formulations combined with precision inhalation devices and integrate a telemedicine platform for real-time monitoring of clinical and environmental data, enabling the early detection of exacerbations and supporting personalized disease management. The expected outcomes include improved diagnostic accuracy, enhanced risk stratification, personalized therapeutic strategies, reduced disease exacerbations, and improved quality of life for patients with inflammatory lung diseases.
Key facts
- Study ID
- NCT07723638
- Run by
- Fondazione Don Carlo Gnocchi ETS
- People needed
- 200
- Starts
- 2026-09-01
- Expected to finish
- 2027-11-13
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults aged 18 years or older.
- Diagnosis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or combined pulmonary fibrosis and emphysema (CPFE), established according to current international diagnostic guidelines.
- Ability and willingness to provide written informed consent.
- Willingness to provide blood and saliva samples for biomarker analyses.
- Willingness and ability to undergo clinical assessments and scheduled follow-up visits.
- Willingness and ability to use study monitoring devices, including environmental monitoring devices and, where applicable, telemedicine tools.
You may not qualify if…
- Age younger than 18 years.
- Inability or unwillingness to provide written informed consent.
- Inability to comply with study procedures or scheduled follow-up.
- Presence of any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, would interfere with study participation or interpretation of the study results.
- Participation in another interventional clinical trial that, in the opinion of the investigator, could interfere with the objectives of this study.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.